Neonatal Phototherapy Devices Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022 - 2027

Anushaa

52
views

Neonatal Phototherapy Devices Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022 - 2027

Neonatal Phototherapy Devices Market size is estimated to reach $132.5 million by 2027, growing at a CAGR of 3.7% during the forecast period 2022-2027.

Neonatal Phototherapy Devices Market size is estimated to reach $132.5 million by 2027, growing at a CAGR of 3.7% during the forecast period 2022-2027. Neonatal Phototherapy is the application of visible light to heal serious jaundice in the neonatal period. The phototherapy utilizes an assortment of 5 high-power LEDs, positioned 30 cm above the patient. The treatment applies great radiation emitted in the blue range of the spectrum, from 400 to 550 nm (the most recommended for Jaundice treatment). The device also offers supplementary functions, like a combined radiometer and treatment time counter. Phytotherapy Is a clear and secure treatment for Neonatal Jaundice. Jaundice is a typical discovery in premature and full-term newborn babies. One of the most efficient and secure techniques for treating neonatal jaundice is utilizing light therapy or phototherapy. This device utilizes fluorescent lamps, tungsten-halogen bulbs, LEDs, optical fibers, and more. Based on Light Source, the Neonatal Phototherapy Devices Market is segmented into Fluorescent Lamps, Light Emitting Diodes (LEDs), Quartz Halogen Lamps, and Gas Discharge Tubes.

The surging application of hospital phytotherapy for the healing of unconjugated hyperbilirubinaemia in pre-term and term babies is set to drive the Neonatal Phototherapy Devices Market. The proliferating government plans, regulations, and arbitrations targeted at limiting the count of neonatal jaundice cases and developing progressive healthcare infrastructure across numerous local markets have heightened the acceptance of technologically advanced neonatal phytotherapy devices involving light sources like fluorescent lamps worldwide and this is set to propel the growth of the Neonatal Phototherapy Devices Market during the forecast period 2022-2027. This represents the Neonatal Phototherapy Devices Industry Outlook.

Report Coverage

The report: “Neonatal Phototherapy Devices Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Neonatal Phototherapy Devices Market.

By Light Source: Fluorescent Lamps, Light Emitting Diodes (LEDs), Quartz Halogen Lamps, Gas Discharge Tubes.

By Product Type: Traditional Physiotherapy Lamps, Phototherapy Beds, Flexible Phototherapy Lamps.

By End User: Hospitals, Neonatal Clinics, Home Users.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

Geographically, North America Neonatal Phototherapy Devices Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the consistent innovation and acceptance of progressive technologies involving light sources like fluorescent lamps in conjunction with surging awareness amidst the people in the North American region.
Neonatal Phototherapy Devices Market growth is being driven by the increasing predominance of neonatal jaundice all through the world in conjunction with the surging application of Neonatal Phototherapy Devices involving light sources like fluorescent lamps. However, current research has offered novel proof that short-term side effects of phytotherapy are inclusive interference with maternal-infant interaction, imbalance of thermal environment and water loss, electrolyte disturbance, bronze baby syndrome, and circadian rhythm disorder, and this is one of the major factors hampering the growth of Neonatal Phototherapy Devices Market.
Neonatal Phototherapy Devices Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Neonatal Phototherapy Devices Market report.

Neonatal Phototherapy Devices Market: Market Share (%) by Region, 2021

For more details on this report - Request for Sample

Neonatal Phototherapy Devices Market Segment Analysis – By Light Source:

The Neonatal Phototherapy Devices Market based on the light sources can be further segmented into Fluorescent Lamps, Light Emitting Diodes (LEDs), Quartz Halogen Lamps, and Gas Discharge Tubes. The Fluorescent Lamps Segment held the largest market share in 2021. This growth is owing to the extensive acceptance of fluorescent lamps for neonatal phototherapy in hospitals and clinics attributed to their accessibility in the market for a greater period of time than other light sources like light-emitting diodes (LEDs). The heightened application of phototherapy involving fluorescent lamps for the treatment of neonatal jaundice as a secure and efficient technique is further propelling the growth of the Fluorescent Lamps segment.

Furthermore, the Light Emitting Diodes (LEDs) segment is estimated to grow with the fastest CAGR of 4.5% during the forecast period 2022-2027 owing to the soaring advantages of LED phototherapy lamps like lower energy intake, a lengthier life span, and decreased costs than fluorescent lamps.

Neonatal Phototherapy Devices Market Segment Analysis – By End User:

The Neonatal Phototherapy Devices Market based on end-user can be further segmented into Hospitals, Neonatal Clinics, and Home Users. The Hospitals segment held the largest market share in 2021. This growth is owing to the rising predominance of neonatal jaundice requiring extensive neonatal phototherapy in hospitals. The effortless availability of trained medical professionals and specialists to handle neonatal phototherapy in hospitals is further propelling the growth of this segment.

Furthermore, the Home Users segment is estimated to grow with the fastest CAGR of 4.7% during the forecast period 2022-2027 owing to the surging benefits of home-based phototherapy involving cases of uncomplicated neonatal jaundice like decreased patient botheration, transportation costs, and hospital waiting time minimized direct and indirect healthcare costs and enhanced mother-baby bonding.

Neonatal Phototherapy Devices Market Segment Analysis – By Geography:

The Neonatal Phototherapy Devices Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and Rest of the World. North America (Neonatal Phototherapy Devices Market) held the largest share with 35% of the overall market in 2021. The growth of this region is owing to the increasing predominance of neonatal jaundice and skin ailments in the North American region. The existence of well-established infrastructure, the accessibility of technologically developed treatment options, and several government initiatives to enhance the health of a newborn baby in the region are further propelling the growth of the Neonatal Phototherapy Devices Market in North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like surging awareness pertaining to progressive phototherapy and enhancing healthcare infrastructure in the Asia-Pacific region. The increasing predominance of neonatal jaundice in newborn babies is further fuelling the progress of the Neonatal Phototherapy Devices Market in the Asia-Pacific region.

Neonatal Phototherapy Devices Market - Drivers

Increasing Predominance Of Neonatal Jaundice Is Projected To Drive The Growth Of Neonatal Phototherapy Devices Market:

As per WHO/Europe, Jaundice is defined as a yellow chromaticity of skin and mucous tissues owing to a raised level of total bilirubin in the blood. Further updates by WHO/Europe indicate that Jaundice is one of the most typical physical signs noticed at the time of the neonatal period is up to 50% of term newborns and 80% of preterm newborns. Phototherapy has been extensively utilized in the handling of Neonatal unconjugated Hyperbilirubinemia for over fifty years. Phototherapy devices involve Fluorescent Lamps, Halogen Lamps, Fiberoptic, or Light-Emitting Diode light sources. Hospital phototherapy is offered by traditional or fibreoptic lights as a treatment to decrease neonatal jaundice. The expanding pervasiveness of neonatal jaundice is therefore fuelling the growth of the Neonatal Phototherapy Devices Market during the forecast period 2022-2027.

Surging Application Of Neonatal Phototherapy Devices Is Expected To Boost The Demand For Neonatal Phototherapy Devices:

Nearly 60% of term babies and 85% of preterm babies will develop clinically apparent jaundice, which typically becomes visible on day 3, peaks on days 5-7, and resolves by 14 days of age in a term infant and by 21 days in the preterm infant. Jaundice is brought about by bilirubin deposition in the skin. Nearly all jaundice in newborn infants is an outcome of raised red cell breakdown and reduced bilirubin excretion. Breastfeeding, haemolysis, and certain metabolic and genetic ailments also raise the hazard of jaundice. Phototherapy may be utilized to treat neonatal jaundice. Blue-green fluorescent light may be more efficient than blue fluorescent light at decreasing the need for phototherapy after 24 hours in healthy low-birth-weight babies with hyperbilirubinaemia in the earliest 4 days of life. Hospital phototherapy utilizing blue LED lamps may be more efficient at decreasing the count of hours spent under phototherapy in comparison with traditional phototherapy (utilizing halogen-quartz bulbs) in term and preterm infants. For distinct intensities of light, close phototherapy in comparison with distant light-source phototherapy may decrease the period of phototherapy and mean serum bilirubin level in infants with hyperbilirubinaemia. Light sources may include fluorescent lamps and quartz halogen lamps. The surging application of neonatal phytotherapy devices is therefore driving the growth of the Neonatal Phototherapy Devices Market during the forecast period 2022-2027.

Neonatal Phototherapy Devices Market – Challenges

Challenges of Phototherapy For Neonatal Hyperbilirubinemia Are Hampering The Growth Of The Neonatal Phototherapy Devices Market:

Numerous investigations have recommended that phototherapy may bring out a series of short? and long-term adverse reactions linked with pediatric ailments, inclusive of hemolysis, allergic ailments, DNA injury, or even cancer. There have been intense adverse reactions to phototherapy for neonatal hyperbilirubinemia. Almost 8% to 11% of neonates develop hyperbilirubinemia. Excluding cases with serious jaundice, phototherapy may typically be disrupted to permit breastfeeding or parent visitations, to permit skin contact and mother-infant interaction, and decrease the anxiety of the parents. Additionally, phototherapy may temporarily influence the vision, hearing, and alertness of the newborn These issues are thus hampering the growth of the Neonatal Phototherapy Devices Market.

Neonatal Phototherapy Devices Industry Outlook:

Novel product launches, mergers & acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Neonatal Phototherapy Devices Market. Key companies of this market are:

GE Healthcare
Atom Medical
Draeger
Koninklijke Philips N.V.
Natus Medical Incorporated
Ningbo David Medical
Shanghai Weyer Electric Co., Ltd
D-Rev
Novos Medical Systems
Advanced Instrumentations Inc.

Recent Developments

In November 2021, GE Healthcare paired AI with novel product launches and partnerships with Optellum and Cambridge. At the Radiological Society of North America’s continuing annual meeting, GE Healthcare not only revealed dozens of novel digital solutions to enhance patient screening, diagnostics, treatment, and monitoring but also contributed extra attention to numerous AI-powered technologies the firm has debuted in current months. The most novel of these is Critical Care Suite 2.0, an AI platform entrenched on a mobile X-ray device to spontaneously compute assessments at the time of scans, triage cases, and supervise quality controls.
In June 2021, at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare demonstrated novel molecular imaging products and solutions and novel opportunities to expand access to radioactive tracers and additional pharmaceutical imaging agents with pride. This boost in access to the most recent and most creative accuracy diagnostics and radiopharmaceuticals – specifically with current FDA clearances of crucial novel therapies – can offer clinicians rare opportunities to make customized care decisions and treatment response evaluations that may assist in enhancing patient outcomes. As an example, GE Healthcare is increasing its U.S. distribution footprint of Vizamyl (flutemetamol F18) by twofold succeeding the FDA's current endorsement of Aduhelm™ (aducanumab), the earliest endorsed treatment for the decrease of beta-amyloid plaques linked with Alzheimer’s disease.
In February 2020, GE Healthcare launched a novel cybersecurity service offering that accumulates medical device knowledge, artificial intelligence, and process management tools to assist hospital groups in their combat against cybersecurity threats. The novel solution, termed Skeye, heightens hospitals’ existing resources and capacities by offering proactive supervision by way of a remote security operations center (SOC) – assisting them to discover, investigate and respond to cybersecurity threats and events in real-time. As more devices become linked, cybersecurity hazard surges – and safety incidents can deeply influence an organization’s output, finances, quality of care, and character.